1. Home
  2. IBIO vs CPIX Comparison

IBIO vs CPIX Comparison

Compare IBIO & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iBio Inc.

IBIO

iBio Inc.

N/A

Current Price

$2.49

Market Cap

50.4M

Sector

Health Care

ML Signal

N/A

Logo Cumberland Pharmaceuticals Inc.

CPIX

Cumberland Pharmaceuticals Inc.

N/A

Current Price

$3.09

Market Cap

73.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IBIO
CPIX
Founded
2008
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
73.6M
IPO Year
2009
2007

Fundamental Metrics

Financial Performance
Metric
IBIO
CPIX
Price
$2.49
$3.09
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$4.75
N/A
AVG Volume (30 Days)
995.4K
136.9K
Earning Date
05-20-2026
06-03-2026
Dividend Yield
N/A
N/A
EPS Growth
73.08
58.70
EPS
N/A
N/A
Revenue
N/A
$42,010,949.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.75
52 Week Low
$0.56
$1.85
52 Week High
$5.60
$6.27

Technical Indicators

Market Signals
Indicator
IBIO
CPIX
Relative Strength Index (RSI) 50.87 33.29
Support Level $0.78 $2.78
Resistance Level $3.01 $3.85
Average True Range (ATR) 0.27 0.32
MACD -0.04 -0.13
Stochastic Oscillator 23.46 3.48

Price Performance

Historical Comparison
IBIO
CPIX

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

About CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Share on Social Networks: